ATE353363T1 - Immunstimulierende zusammensetzung und verfahren - Google Patents

Immunstimulierende zusammensetzung und verfahren

Info

Publication number
ATE353363T1
ATE353363T1 AT96944879T AT96944879T ATE353363T1 AT E353363 T1 ATE353363 T1 AT E353363T1 AT 96944879 T AT96944879 T AT 96944879T AT 96944879 T AT96944879 T AT 96944879T AT E353363 T1 ATE353363 T1 AT E353363T1
Authority
AT
Austria
Prior art keywords
polypeptide
immuno
disclosed
therapeutic compositions
stimulating composition
Prior art date
Application number
AT96944879T
Other languages
English (en)
Inventor
Reiner Laus
Curtis Landon Ruegg
Hongyu Wu
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Application granted granted Critical
Publication of ATE353363T1 publication Critical patent/ATE353363T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT96944879T 1995-12-28 1996-12-23 Immunstimulierende zusammensetzung und verfahren ATE353363T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/579,823 US6080409A (en) 1995-12-28 1995-12-28 Immunostimulatory method

Publications (1)

Publication Number Publication Date
ATE353363T1 true ATE353363T1 (de) 2007-02-15

Family

ID=24318489

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96944879T ATE353363T1 (de) 1995-12-28 1996-12-23 Immunstimulierende zusammensetzung und verfahren

Country Status (12)

Country Link
US (3) US6080409A (de)
EP (1) EP0870022B1 (de)
JP (1) JP3908277B2 (de)
AT (1) ATE353363T1 (de)
AU (1) AU716783B2 (de)
CA (1) CA2241373C (de)
DE (1) DE69636891T2 (de)
DK (1) DK0870022T3 (de)
ES (1) ES2281087T3 (de)
NZ (2) NZ326092A (de)
PT (1) PT870022E (de)
WO (1) WO1997024438A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
AU703120B2 (en) 1995-10-20 1999-03-18 University Of Nebraska Board Of Regents Composition and methods for enhancing immune responses mediated by antigen-presenting cells
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
DE69840326D1 (de) * 1997-03-27 2009-01-22 Csl Ltd Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
US6642013B1 (en) * 1997-08-21 2003-11-04 The University Of Arkansas For Medical Sciences Extracellular serine protease
US7157084B2 (en) * 1997-08-21 2007-01-02 The Board Of Trustees Of The University Of Arkansas System Extracellular serine protease
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
EP1104456A1 (de) * 1998-08-10 2001-06-06 Chiron Corporation Genmanipulierte antigenpräsentierende zellen die eine antigengruppe präsentieren, und deren verwendungen
US7351546B2 (en) 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
ATE407206T1 (de) * 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1228214A2 (de) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietinformen mit verbesserten eigenschaften
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
AU2001239873A1 (en) 2000-02-24 2001-09-03 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP2003528605A (ja) 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
ATE507295T1 (de) 2000-03-30 2011-05-15 Dendreon Corp Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
KR100643818B1 (ko) * 2000-05-08 2006-11-10 셀덱스 쎄라퓨틱스, 인크. 수상세포에 대한 인간 모노클로날 항체
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
JP5390055B2 (ja) * 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
SG143058A1 (en) * 2000-08-11 2008-06-27 Favrille Inc Method and composition for altering a t cell mediated pathology
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
HUP0303428A2 (hu) * 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
CN1541113A (zh) * 2001-04-27 2004-10-27 �Ƹ��� 利用激活的t细胞使抗原提呈细胞成熟
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
WO2003024312A2 (en) * 2001-09-17 2003-03-27 Valeocyte Therapies Llc Cell therapy system
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
WO2003087338A2 (en) * 2002-04-11 2003-10-23 Amgen, Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20060292618A1 (en) * 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
EP1572929B1 (de) * 2002-06-12 2011-05-11 Gavish-Galilee Bio Applications Ltd "mit mhc-klasse-i-peptidepitopen kovalent verkn pftes membranverankertes beta2-mikroglobulin"
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
US20040048258A1 (en) * 2002-09-10 2004-03-11 Windber Research Institute Multiple-gene diagnostic probes and assay kits and method for the assessment of multiple markers for breast cancer prognosis
WO2004024075A2 (en) * 2002-09-11 2004-03-25 Medical College Of Georgia Research Institute, Inc. Chemokine receptor antagonists as therapeutic agents
CA2497554A1 (en) * 2002-09-20 2004-04-01 Dendreon Corporation Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
US7179797B2 (en) * 2002-09-27 2007-02-20 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
US20040142328A1 (en) * 2003-01-06 2004-07-22 Windber Research Institute Method and cloning vector for preparing multiple-gene diagnostic probes for the assessment of multiple markers for breast cancer prognosis
US9243064B2 (en) * 2003-01-31 2016-01-26 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US20060134067A1 (en) * 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
EP2463299A3 (de) 2003-03-05 2012-10-17 Dendreon Corporation Zusammensetzungen und Verfahren unter Anwendung von Polypeptiden mit alternativem Leserahmen zur Behandlung von Krebs und Infektionskrankheiten
EP2090586A1 (de) * 2003-06-25 2009-08-19 BN ImmunoTherapeutics, Inc. Aufreinigung von her-2 Varianten
EA008827B1 (ru) * 2003-06-25 2007-08-31 Фармекса А/С Очистка вариантов her-2
US20050201992A1 (en) * 2004-03-15 2005-09-15 Moviglia Gustavo A. Tumor/B-cell hybrid cells and uses thereof
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
JP2008527981A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 治療目的および診断目的のためにパラメーターにより選択されたｇｍ−ｃｓｆ、ｉｌ−３、ｉｌ−４、ｉｌ−５、ならびにそのキメラ
US8668905B2 (en) * 2005-05-12 2014-03-11 University Of South Florida P53 vaccines for the treatment of cancers
KR100647847B1 (ko) * 2005-05-27 2006-11-23 크레아젠 주식회사 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2626238C (en) * 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
DE602007005354D1 (de) * 2006-01-25 2010-04-29 Viro Pharmaceuticals Gmbh & Co Humaner verstärker der viralen infektion (sevi) und seine anwendung
US8361479B2 (en) * 2006-08-11 2013-01-29 Dendreon Corporation Promiscuous PAP CD4 T cell epitopes
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2665568C (en) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
US8153120B2 (en) * 2007-03-22 2012-04-10 Dendreon Corporation Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity
KR101811965B1 (ko) 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
US8666674B2 (en) * 2009-07-28 2014-03-04 Promising Future, Llc Pairing processes for preparing reactive cytotoxic T cells
US20150284444A1 (en) * 2012-02-16 2015-10-08 Masami Watanabe Pharmaceutical composition for cancer treatment including fusion protein
US10022402B2 (en) 2012-12-03 2018-07-17 Subhadra Dravida Allogenic mesendritic vector for ovarian cancer
WO2015036646A1 (es) 2013-09-13 2015-03-19 Fundación Pública Andaluza Progreso Y Salud Combinaciones de proteínas agregantes y chaperonas moleculares para el tratamiento de proteinopatías o enfermedades conformacionales
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
JP6985939B2 (ja) * 2015-06-30 2021-12-22 ノースウエスト バイオセラピューティクス，インコーポレイティド 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞
US20170107580A1 (en) 2015-10-15 2017-04-20 Dendreon Pharmaceuticals, Inc. Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t
EP3173098A1 (de) 2015-11-27 2017-05-31 Assistance Publique-Hopitaux De Paris Immunstimulierende zusammensetzungen
US10130658B2 (en) 2015-12-18 2018-11-20 Provectus Pharmatech, Inc. Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
CN105647970A (zh) * 2016-02-22 2016-06-08 河北利同康生物科技有限公司 前列腺癌特异性pap-gm-csf-il-6基因重组融合蛋白及其制备方法
CN110079539B (zh) * 2018-01-25 2022-07-01 上海惠盾因泰生物科技有限公司 前列腺酸性磷酸酶/粒-巨噬细胞集落刺激因子制备方法
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
AU2019333181B2 (en) * 2018-08-31 2025-10-02 The Research Institute At Nationwide Children's Hospital Chimeric oncolytic herpesvirus that stimulate an antitumor immune response
US20220088183A1 (en) * 2018-08-31 2022-03-24 The Research Institute At Nationwide Children's Hospital Chimeric oncolytic herpesvirus that stimulates an antitumor immune response
CN110358735B (zh) * 2019-06-24 2021-09-21 广州安捷生物医学技术有限公司 一种ctl细胞的制备方法及应用
EP3868401A1 (de) 2020-02-21 2021-08-25 Assistance Publique Hôpitaux de Paris Optimierung der peptid-melanin-bindung.
CA3192967A1 (en) 2020-10-15 2022-04-21 Aiquan CHANG Recombinant adeno-associated virus vectors with cd14 promoter and use thereof
WO2022174052A1 (en) * 2021-02-12 2022-08-18 The Wistar Institute Of Anatomy And Biology Consensus prostate antigens, nucleic acid molecules encoding the same, and vaccines and uses comprising the same
EP4382121A1 (de) 2022-12-07 2024-06-12 Altevax Impfstoffe gegen ptprz1-positive tumore
EP4420677A1 (de) 2023-02-22 2024-08-28 Altevax Impfstoffe gegen tert-positive tumoren

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
GB8722741D0 (en) * 1987-09-28 1987-11-04 Hoffmann La Roche Induction of cytotoxic t cell response
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0406857B1 (de) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteine und deren Herstellung
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
DE69333433T2 (de) * 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
WO1994021287A1 (en) * 1993-03-15 1994-09-29 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Peptide coated dendritic cells as immunogens
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
CA2192655A1 (en) * 1994-06-14 1995-12-21 Edgar G. Engleman Methods for in vivo t cell activation by antigen-pulsed dendritic cells
AU686840B2 (en) * 1994-07-07 1998-02-12 Immunex Corporation Fusion proteins comprising GM-CSF and antigens and their expression in yeast
GB9501079D0 (en) * 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
AU5801896A (en) * 1995-05-23 1996-12-11 Scripps Research Institute, The Antigen-specific activation of unprimed cd8+ t cells

Also Published As

Publication number Publication date
US6080409A (en) 2000-06-27
PT870022E (pt) 2007-04-30
DE69636891T2 (de) 2007-12-06
AU1338097A (en) 1997-07-28
NZ500665A (en) 2005-06-24
CA2241373C (en) 2013-04-09
AU716783B2 (en) 2000-03-09
JP2000502567A (ja) 2000-03-07
EP0870022B1 (de) 2007-02-07
US6210662B1 (en) 2001-04-03
WO1997024438A1 (en) 1997-07-10
CA2241373A1 (en) 1997-07-10
DK0870022T3 (da) 2007-05-21
US5976546A (en) 1999-11-02
NZ326092A (en) 1999-11-29
ES2281087T3 (es) 2007-09-16
DE69636891D1 (de) 2007-03-22
EP0870022A1 (de) 1998-10-14
JP3908277B2 (ja) 2007-04-25

Similar Documents

Publication Publication Date Title
DE69636891D1 (de) Immunstimulierende zusammensetzung und verfahren
AU2210899A (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
CA2290485A1 (en) Method for the production of non-immunogenic proteins
NZ288883A (en) Conjugates comprising coagulation factors
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
DE69418699D1 (de) Induktion der antworten zytotoxischer t-lymphozyten
EP0986372A4 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
RU94024566A (ru) Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики
GR3035440T3 (en) Therapeutic uses of bpi protein products for human meningococcemia
EP0859625A4 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
ATE221125T1 (de) Klonierte glutaminsäure-decarboxylase
AU2741897A (en) Suppression of immune response via inhibition of cathepsin s
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
PL319040A1 (en) Modified proteins
DE60144516D1 (de) Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
WO2024238955A3 (en) Relaxin-2 fusion protein analogs and methods of using same
PT948319E (pt) Celulas encapsuladas produtoras de anticorpos
IT1068206B (it) Procedimento per l'ottenimento di prodotti arricchiti in proteine da glutine di cereali
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
AU3823601A (en) Cytotoxic t lymphocytes activated by dendritic cell hybrids
DE69529229D1 (de) Verfahren und testsätze mit makrophagen stimulierenden proteinen
DE69426303D1 (de) Verfahren zur unterdrückung der immunantwort durch gentherapie
Frank et al. Immunobiology of brain tumors
AR002243A1 (es) Anticuerpos contra proteinas alogenicas y xenogenicas, su uso en diagnostico y terapia y metodos para la determinacion de los mismos.
AU7940594A (en) Human foam cells and methods for preparing them, monoclonal antibodies to said foam cells and their pharmaceutical and diagnostic use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0870022

Country of ref document: EP